Bracco, a global leader in diagnostic imaging, today announced that the U.S. Food and Drug Administration (FDA) has approved ...

In the U.S., Elucirem is indicated in adults and now in pediatric patients including term neonates, for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal ...

WARNING:  RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS (NSF)   Risk Associated with Intrathecal Use Intrathecal administration of gadolinium-based ...

Itvisma should only be administered intrathecally using a lumbar puncture by health care professionals experienced in performing the procedure. The Food and Drug Administration has approved Itvisma ® ...

Credit: Novartis. The approval was supported by data from phase 3 STEER study, which enrolled patients with SMA who were treatment-naive and able to sit but never able to walk independently. Itvisma ...

What is Itvisma for SMA? Itvisma (onasemnogene abeparvovec-brve) is a one-time gene therapy that’s approved for adults and children, 2 years and older, with spinal muscular atrophy (SMA). Itvisma is ...

The FDA has approved onasemnogene abeparvovec-brve (Itvisma, Novartis), an adeno-associated virus vector-based gene therapy for treatment of spinal muscular atrophy (SMA) in patients aged 2 years and ...

Novartis has received an FDA approval for Itvisma, a new version of the company’s gene therapy Zolgensma, to treat older patients with spinal muscular atrophy (SMA). The approval comes more than six ...